|
Inadequate Investigations Into Drug Defects Prompt 483 for Millennium
Quality control personnel at Millennium Pharmaceuticals’ Cambridge, Mass., facility failed to adequately investigate particles found in several lots of contract-manufactured Velcade, an injectable oncology drug, an FDA Form 483 states.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives